TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3136608

Group type: EXPERIMENTAL
Intervention: 0.8 X 10(9) bacterial equivalents (BE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.2 X 10(9) BE
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.6 X 10(9) BE
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.6 X 10(9) BE (on days 0 and 28)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All concentrations of vaccine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Individuals with high pre‐immunisation‐titres
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Individuals with low pre‐immunisation‐titres
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ELISA titre
Number of subjects: 36
Study: 31837276

Group type: EXPERIMENTAL
Intervention: Standardised home exercise jaw opening and chewing programmes, and home oral hygiene measures instructed and controlled by a trained dentist.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control period without intervention.
Number of subjects: 29
Study: 30735139

Group type: EXPERIMENTAL
Intervention: Internet-based healthy lifestyle program (Time2bHealthy) for 11 weeks, followed by fortnightly emails for 3 months.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison group received email communication only.
Number of subjects: 86
Study: 28604618

Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (2 × 75 mg/day) for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo capsules for 4 weeks
Number of subjects: 45
Study: 25698163

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Prescriptive Advice (PA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 53
Study: 24014603

Group type: EXPERIMENTAL
Intervention: Follicular flushing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Direct aspiration
Number of subjects: 50
Study: 21320084

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene or supraclavicular nerve blocks
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 257
Study: 17439539

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 1.5 microm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 2.5 microm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 4.5 microm
Number of subjects: 10
Study: 16307696

Group type: EXPERIMENTAL
Intervention: Metopimazine (15 mg tid) with methylprednisolone (48 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Ondansetron (8 mg bid) with methylprednisolone (48 mg)
Number of subjects: 99
Study: 11950706

Group type: EXPERIMENTAL
Intervention: Low HDL levels (hyperlipidemic)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low HDL levels (normolipidemic)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Average HDL levels (hyperlipidemic)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Average HDL levels (normolipidemic)
Number of subjects: 65

Group type: COMPARATOR
Intervention: High HDL levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment in 20 low-HDL subjects
Number of subjects: 65
Study: 10710176

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (low doses in the afternoon)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 5
Study: 7628885

Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulant treatment after myocardial infarction
Number of subjects: 350

Group type: COMPARATOR
Intervention: Eligible non-participants
Number of subjects: 350
Study: 2487802

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg a day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nifedipine retard 20 mg b.i.d.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg and Nifedipine retard 20 mg once a day
Number of subjects: 44
Study: 937070

Group type: EXPERIMENTAL
Intervention: Non-invasive ultrasound Doppler technique
Number of subjects: 35
Study: 31629805

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% BID
Number of subjects: 307

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 307
Study: 27689690

Group type: EXPERIMENTAL
Intervention: foam-fluid hybrid cushions
Number of subjects: 78

Group type: COMPARATOR
Intervention: air-filled and foam cushions
Number of subjects: 78
Study: 27301456

Group type: EXPERIMENTAL
Intervention: PLA2G7 V279F variant
Number of subjects: 91428
Study: 25516316

Group type: EXPERIMENTAL
Intervention: Turmeric (1 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cinnamon (2 g)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Turmeric (1 g) with white bread
Number of subjects: 48
Study: 22883034

Group type: EXPERIMENTAL
Intervention: Fortified human milk (FHM)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 125
Study: 20557267

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18362932

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 40
Study: 16026656

Group type: EXPERIMENTAL
Intervention: 8-week multiple risk modification group program
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care with standard physical exercise training
Number of subjects: 184
Study: 12860337

Group type: EXPERIMENTAL
Intervention: Extraamniotic prostaglandin E2 (PGE2) applied in serial doses of 200 mcg every 2 h up to 20 doses.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of oxytocin added when fetus was not expelled.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Curettage performed in the majority of patients.
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (women without a uterine scar).
Number of subjects: 262
Study: 10923280

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day for 12 weeks
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day for 12 weeks
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 8638517

Group type: EXPERIMENTAL
Intervention: 5 ppm hydrogen sulfide (H2S) inhalation
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0 ppm (control)
Number of subjects: 25
Study: 1433583

Group type: EXPERIMENTAL
Intervention: Surgical treatment (reimplantation)
Number of subjects: 151
Study: 2578653

Group type: EXPERIMENTAL
Intervention: Atrioventricular synchronous pacing
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ventricular inhibited pacing
Number of subjects: 44
Study: 31254596

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg/day for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29283177

Group type: EXPERIMENTAL
Intervention: UAB criteria (AVF outflow vein lumen diameter ≥4 mm and blood flow ≥500 mL/min)
Number of subjects: 105

Group type: COMPARATOR
Intervention: NKF criteria (AVF outflow vein lumen diameter ≥6 mm and blood flow ≥600 mL/min)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: UAB criteria for radiocephalic AVFs
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: UAB and NKF criteria for brachiocephalic AVFs
Number of subjects: 105
Study: 26750378

Group type: EXPERIMENTAL
Intervention: Concentrated ambient coarse PM (164.2 ± 80.4 μg/m(3))
Number of subjects: 29

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 29
Study: 25336193

Group type: EXPERIMENTAL
Intervention: Stent plus palliative radiotherapy (20 Gy in five fractions over one week or 30 Gy in 10 fractions over two weeks)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Stent alone
Number of subjects: 496
Study: 21691139

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vicryl sutures
Number of subjects: 20
Study: 20838372

Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg kg‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Landiolol (0.2 mg kg‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (0.1 mL kg‐1 saline)
Number of subjects: 90
Study: 17949392

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Twelve-step facilitation (TSF)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 812
Study: 16055638

Group type: EXPERIMENTAL
Intervention: Canadian participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Japanese participants
Number of subjects: 0
Study: 12153738

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX), 0.1 mg twice daily for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard meal at 0, 24, 36 and 48 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard meal at 0 and 48 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting for 48 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no DEX)
Number of subjects: 0
Study: 10343536

Group type: EXPERIMENTAL
Intervention: 99Tcm‐MDP bone scintigraphy
Number of subjects: 58
Study: 9035660

Group type: EXPERIMENTAL
Intervention: Nasal douche (saline solution)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hand irrigation (saline solution)
Number of subjects: 36
Study: 1820757

Group type: EXPERIMENTAL
Intervention: Lithium augmentation for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium augmentation for 4 weeks
Number of subjects: 30
Study: 6366345

Group type: EXPERIMENTAL
Intervention: 1% Indomethacin solution, 1 drop 4 times daily for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, 1 drop 4 times daily for 3 months
Number of subjects: 0
Study: 31480637

Group type: EXPERIMENTAL
Intervention: Chronic dietary fat intake (varied in saturated, polyunsaturated, and monounsaturated fatty acid composition)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Acute dietary fat intake (MUFA-rich meals)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Postprandial MUFA-rich meals
Number of subjects: 218
Study: 29568003

Group type: EXPERIMENTAL
Intervention: Whey protein (28g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ca-caseinate (28g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Maltodextrin (27g)
Number of subjects: 27
Study: 26965317

Group type: EXPERIMENTAL
Intervention: Delayed clamping of the umbilical cord (≥180 s after delivery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early clamping of the umbilical cord (≤60 s)
Number of subjects: 0
Study: 23192897

Group type: EXPERIMENTAL
Intervention: Astaxanthin (Asx)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Astaxanthin (Asx) and Placebo (P)
Number of subjects: 40
Study: 21388398

Group type: EXPERIMENTAL
Intervention: Hormones secreted by the pituitary gland
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Releasing factors characterized as peptides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical use of neuroendocrinology findings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demonstration of ubiquity of releasing factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implications in control of behavior
Number of subjects: 0
Study: 19880578

Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine lozenge
Number of subjects: 270
Study: 17009067

Group type: EXPERIMENTAL
Intervention: Insulin infusion (4-6 IU/hour for 3-5 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Insulin infusion + pioglitazone (15 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Insulin infusion without pioglitazone
Number of subjects: 28
Study: 15497603

Group type: EXPERIMENTAL
Intervention: Holistic interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo effect
Number of subjects: 0
Study: 11050517

Group type: EXPERIMENTAL
Intervention: BIPAP
Number of subjects: 24

Group type: COMPARATOR
Intervention: S-IMV/PSV
Number of subjects: 24

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 24
Study: 9062089

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard coronary angioplasty
Number of subjects: 120
Study: 8398325

Group type: EXPERIMENTAL
Intervention: Surgical tetracycline pleurodesis
Number of subjects: 34

Group type: COMPARATOR
Intervention: Medical tetracycline pleurodesis
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both surgical and medical tetracycline pleurodesis
Number of subjects: 34
Study: 2878025

Group type: EXPERIMENTAL
Intervention: Changing administration sets every 24 h
Number of subjects: 387

Group type: COMPARATOR
Intervention: Changing administration sets every 120 h
Number of subjects: 387
Study: 30558592

Group type: EXPERIMENTAL
Intervention: Combined neuromuscular exercise and back care counseling
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 219

Group type: COMPARATOR
Intervention: No intervention Control
Number of subjects: 219
Study: 27057222

Group type: EXPERIMENTAL
Intervention: Hyperosmolar sodium lactate (HSL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium chloride 3% (HSS)
Number of subjects: 60
Study: 25470094

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 22842368

Group type: EXPERIMENTAL
Intervention: Combination exercise training (15 weeks, 2 sessions per week of walking and 2 sessions per week of resistance training)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 29
Study: 20566009

Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus zoledronic acid (4 mg intravenously every 3 months)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Goserelin acetate alone
Number of subjects: 200
Study: 18954634

Group type: EXPERIMENTAL
Intervention: Stentless bioprostheses (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Stented bioprostheses (group B)
Number of subjects: 62
Study: 19368963

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) score treatment
Number of subjects: 586
Study: 14685645

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 74
Study: 11772961

Group type: EXPERIMENTAL
Intervention: 40 mg oral baclofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9466096

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Metoclopramide 0.4 mg kg‐1
Number of subjects: 96
Study: 7930718

Group type: EXPERIMENTAL
Intervention: gp160-recombinant vaccinia virus (HIVAC-1e) followed by recombinant (r) gp160 boosting
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HIVAC-1e-primed vaccinees
Number of subjects: 29
Study: 3335729

Group type: EXPERIMENTAL
Intervention: Habit training alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Habit training and placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Habit training and oxybutynin (2.5 mg three times daily for 1 week, then 5 mg three times daily for 1 week)
Number of subjects: 15
Study: 11317473

Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31142294

Group type: EXPERIMENTAL
Intervention: Combined exercise training (aerobic and strength) three times per week for 12 weeks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Health education intervention once a week for 12 weeks
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 184

Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 184
Study: 29621568

Group type: EXPERIMENTAL
Intervention: Experimental solution containing NaF/TiF4 (189 ppm Ti+4, 500 ppm F‐, pH 4.4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Commercial solution containing SnCl2/NaF/AmF (800 ppm Sn+2, 500 ppm F‐, pH 4.5, Elmex®/GABA, positive control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 15
Study: 27697553

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methamphetamine 15 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methamphetamine 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg + Methamphetamine 15 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg + Methamphetamine 30 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buspirone 0 mg + Methamphetamine 15 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buspirone 0 mg + Methamphetamine 30 mg
Number of subjects: 10
Study: 27437463

Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ferric sulfate (FS)
Number of subjects: 70
Study: 22559200

Group type: EXPERIMENTAL
Intervention: Low intensity stress-management intervention (first step for all patients)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: More intensive stress-management intervention (group setting or individually)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation of the intervention
Number of subjects: 300
Study: 21298840

Group type: EXPERIMENTAL
Intervention: Centella asiatica extract capsule (50 mg of extracted asiaticoside per capsule, 2 capsules after meals, three times a day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 17682639

Group type: EXPERIMENTAL
Intervention: 35% potassium nitrate/20% benzocaine/10% tetracaine/aqueous hydroxyethyl cellulose gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydroxyethyl cellulose without active agents
Number of subjects: 100
Study: 16091398

Group type: EXPERIMENTAL
Intervention: Local steroid injection
Number of subjects: 207

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Local steroid injection and Physiotherapy
Number of subjects: 207
Study: 12401641

Group type: EXPERIMENTAL
Intervention: Tandospirone 30 mg (T30 group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tandospirone 10 mg (T10 group)
Number of subjects: 90
Study: 10091630

Group type: EXPERIMENTAL
Intervention: One piribedil patch (1 PP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Two piribedil patches (2 PP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7792499

Group type: EXPERIMENTAL
Intervention: Prophylactic naps (0, 2, 4 or 8 hours)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Single 400-mg dose of caffeine
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Repeated doses of caffeine (150 or 300 mg every 6 hours)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo control (no nap and placebo administered every 6 hours)
Number of subjects: 140
Study: 2237331

Group type: EXPERIMENTAL
Intervention: Minnesota model treatment for alcohol abuse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient treatment for alcohol abuse
Number of subjects: 0
Study: 327652

Group type: EXPERIMENTAL
Intervention: Subcutaneous bethanechol chloride 5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral bethanechol chloride 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral bethanechol chloride 200 mg
Number of subjects: 20
Study: 30860573

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus AKT inhibitor capivasertib
Number of subjects: 59

Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both interventions (capivasertib and placebo)
Number of subjects: 59
Study: 29149912

Group type: EXPERIMENTAL
Intervention: UC with process incentive
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: UC with outcome incentive
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (UC) only
Number of subjects: 240
Study: 24408035

Group type: EXPERIMENTAL
Intervention: Parenteral ω‐3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 60
Study: 24320057

Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen with anti-inflammatory agents starting on the first day after laser treatment.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control side treated with petrolatum ointment only.
Number of subjects: 30
Study: 22741251

Group type: EXPERIMENTAL
Intervention: Acupuncture of reinforcing kidney and activating spleen
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcium Carbonate D3 tablets (600 mg, twice a day)
Number of subjects: 72
Study: 19541657

Group type: EXPERIMENTAL
Intervention: Remote-association task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word fragment completion task
Number of subjects: 0
Study: 17253178

Group type: EXPERIMENTAL
Intervention: ginsenoside Rg3 combined with mitomycin C and tegafur (MF)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Mitomycin C+Tegafur (MF)
Number of subjects: 71
Study: 15204148

Group type: EXPERIMENTAL
Intervention: New regimen of fusidic acid suspension (20 mg/kg divided b.i.d.)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard regimen of fusidic acid suspension (50 mg/kg divided t.i.d.)
Number of subjects: 430
Study: 14615175

Group type: EXPERIMENTAL
Intervention: Silicone breast implants (SBI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (normal population)
Number of subjects: 84
Study: 11285961

Group type: EXPERIMENTAL
Intervention: Heated CO2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard CO2 (Control)
Number of subjects: 40